Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers.